BPC-157

What people use it for

• Injury recovery (injected near the injury site when possible)S1
• Gut problems such as IBS and gastritis (oral use)S1S2
• General wellness and prevention at lower amountsS1

Reported regimens

Reported side effects

• mild redness, swelling or small bumps at the injection siteS2S3
• mild dizziness and nausea, usually settling within 24 to 72 hoursS2
• headache, light-headedness or fatigue, mostly in the first few daysS2

Reported benefits (claims, not shown in trials)

• faster healing of tendon, muscle and gut problems (self-reported, no controls)S1

Cautions

• The community protocols are anecdotal experiences, not clinical evidence.S1
• S4 says these products are unregulated. S1 says product quality and purity vary a lot between vendors.S1S4
• Very little human clinical trial data exists. Most studies were in rodents.S6
• Sources flag a theoretical concern about cancer growth, because BPC-157 promotes new blood vessel growth in animal models.S2S3
• S4 says BPC-157 has poor oral bioavailability and is broken down in the gut, which compromises oral forms.S4

Status notes

• As of 2026-10-30, HHS's draft policy says it does not plan to act against licensed pharmacies or physicians that make BPC-157 acetate for a patient with a prescription, under strict conditions. It gives no legal rights and does not bind HHS or the public. It does not grant FDA approval or add the substance to the 503A bulks list, the list of ingredients allowed for this compounding. The listed routes are under the skin (subcutaneous), into a muscle (intramuscular), by mouth (oral), or on the skin (topical).S10S11
• Only a licensed pharmacist in a state-licensed pharmacy or federal facility, or a licensed physician, can compound under this policy. They need a valid prescription for the individual patient. The original manufacturer must register with FDA under section 510 and meet current good manufacturing practice (CGMP) standards and other applicable federal drug requirements. A valid certificate of analysis, the batch's test report, must identify the manufacturing site and meet Appendix B's testing standards. The ingredient must match Appendix B's identity, including its amino acid sequence, chemical structure, molecular weight, and molecular formula. Tests must cover identity, purity, potency, and harmful contaminants, including endotoxins, heavy metals, microbes, and impurities. If an FDA-registered repacker, relabeler, or reseller supplies it, that business must document checks of the original manufacturer and its certificate. The product must contain only one active ingredient from Appendix A.S10
• Compounders must report products, serious adverse events, and product quality problems to FDA and the states where they make and send the products. Each product report must give the active ingredient, its strength per unit, the original manufacturer, and the manufacturing facility's unique identifier. It must also give the dosage form and route. Compounders must report serious adverse events to FDA MedWatch even if they do not consider the drug responsible. The patient's label must explain how to report adverse events and problems with identity, strength, purity, or quality. It must state: "This is a compounded drug product. Not for resale."S10
• For oral products, compounders must document adequate absorption into the bloodstream in humans for the exact formulation given to the patient. Any device packaged with the drug, or containing it, must be an FDA 510(k)-cleared syringe. All other applicable federal drug requirements still apply, including sanitary conditions.S10
• This 503A policy does not cover 503B outsourcing facilities, research chemicals, supplements, or blends. It applies only until a final rule includes or excludes the substance from the 503A bulks list. HHS may reconsider the policy, including if safety or product quality problems arise.S10
• Federal Register document 2026-22192 was filed on 2026-10-28 and published on 2026-10-30. Docket: HHS-OASH-2026-0496. The notice allows comments for two weeks after publication. That gives a comment date of 2026-11-13.S11
• On 2026-07-23 the FDA Pharmacy Compounding Advisory Committee voted 8-6, with one abstention, to recommend BPC-157 for the 503A bulks list. The vote is advisory. BPC-157 is not FDA-approved.S5S6
• Sources use Pentadeca arginate, PDA, and BPC-157 arginate for BPC-157 paired with arginine. They give the unchanged sequence GEPPPGKPADDAGLV. The salt is not an added arginine residue in the peptide chain.S7S8
• The patent describes arginine salts of this peptide. It does not establish that every marketed PDA product matches its preparation. A different salt does not establish approval, safety, absorption, or clinical equivalence.S7S8

Community sources

• S1BPC-157: Community Protocols & Reportspeptideprotocolwiki.comcarries seller links, not linked
• S2BPC-157 side effects guide (opens in a new tab)peptide-db.com
• S3BPC-157 Dosing Guide: Protocol, Reconstitution & Safetypeptidedosingprotocols.comcarries seller links, not linked
• S4BPC-157 peptide: benefits, safety, legal status and research (opens in a new tab)bscg.org
• S5FDA Panel Votes to Loosen Restrictions for Four Peptides (opens in a new tab)pharmexec.com
• S6FDA advisory committee votes to add popular peptide BPC-157 to drug compounding list (opens in a new tab)goodmorningamerica.com
• S7Primary patent for BPC-157 basic-amino-acid salts (opens in a new tab)patents.google.com
• S8Pentadeca arginate identity and source comparison (opens in a new tab)kalios.health
• S10HHS interim 503A peptide enforcement policy, Appendix B (opens in a new tab)hhs.gov
• S11Federal Register 2026-22192, published 2026-10-30 (opens in a new tab)federalregister.gov

plus 1 seller page (not linked)